EIGR.Q Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Eiger BioPharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.50 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$1.10 |
| Beta | 2.78 |
| 11 Month Change | -15.00% |
| 3 Month Change | -35.11% |
| 1 Year Change | -14.14% |
| 33 Year Change | -95.92% |
| 5 Year Change | -97.10% |
| Change since IPO | -98.22% |
Recent News & Updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon
Apr 06Shareholder Returns
| EIGR.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | 1.9% |
| 1Y | -14.1% | 18.7% | 32.8% |
Return vs Industry: EIGR.Q underperformed the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: EIGR.Q underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| EIGR.Q volatility | |
|---|---|
| EIGR.Q Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EIGR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: EIGR.Q's weekly volatility has decreased from 38% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | David Apelian | www.eigerbio.com |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. Fundamentals Summary
| EIGR.Q fundamental statistics | |
|---|---|
| Market cap | US$12.59m |
| Earnings (TTM) | -US$74.96m |
| Revenue (TTM) | US$15.77m |
0.8x
P/S Ratio-0.2x
P/E RatioIs EIGR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EIGR.Q income statement (TTM) | |
|---|---|
| Revenue | US$15.77m |
| Cost of Revenue | US$24.00k |
| Gross Profit | US$15.75m |
| Other Expenses | US$90.71m |
| Earnings | -US$74.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -50.62 |
| Gross Margin | 99.85% |
| Net Profit Margin | -475.26% |
| Debt/Equity Ratio | -284.4% |
How did EIGR.Q perform over the long term?
See historical performance and comparison